CO5700792A2 - Un agente preventivo para la vasculitis - Google Patents

Un agente preventivo para la vasculitis

Info

Publication number
CO5700792A2
CO5700792A2 CO06069184A CO06069184A CO5700792A2 CO 5700792 A2 CO5700792 A2 CO 5700792A2 CO 06069184 A CO06069184 A CO 06069184A CO 06069184 A CO06069184 A CO 06069184A CO 5700792 A2 CO5700792 A2 CO 5700792A2
Authority
CO
Colombia
Prior art keywords
preventive
vasculitis
receptor
therapeutic agent
antibody against
Prior art date
Application number
CO06069184A
Other languages
English (en)
Inventor
Norihiro Nishimoto
Tadamitsu Kishimoto
Hideko Nakahara
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34708761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700792(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CO5700792A2 publication Critical patent/CO5700792A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1.- Un agente preventivo y/o terapéutico para la vasculitis, comprendiendo dicho agente un antagonista de inteneuquina 6 (IL-6) como componente activo.2.- Un agente preventivo y/o terapéutico para la vasculitis que posee resistencia a esteroides y/o inmunosupresores, comprendiendo dicho agente un antagonista de interleuquina 6 (IL-6) como componente activo.3.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 1 o 2 en el cual dicha vasculitis es la poliarteritis nudosa.4.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 1 o 2 en el cual la vasculitis es el síndrome de aortitis.5.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 1 o 2 en el cual la vasculitis es la vasculitis asociada con anormalidades inmunológicas.6.- El agente preventivo y/o terapéutico de acuerdo con cualquiera de las reivindicaciones 1 a 5 en el cual dicho antagonista de IL-6 es un anticuerpo contra el receptor de IL-6.7.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 6 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo monoclonal contra el receptor de IL-6.8.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 6 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo monoclonal contra el receptor humano de IL-6.9.- El agente preventivo y/o terapéutico de acuerdo con la reivindicación 6 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo monoclonal contra el receptor de IL-6 de ratón.10.- El agente preventivo y/o terapéutico de acuerdo con cualquiera de las reivindicaciones 6 a 9 en el cual dicho anticuerpo contra el receptor de IL-6 es un anticuerpo recombinante.
CO06069184A 2003-12-19 2006-07-14 Un agente preventivo para la vasculitis CO5700792A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003423517 2003-12-19

Publications (1)

Publication Number Publication Date
CO5700792A2 true CO5700792A2 (es) 2006-11-30

Family

ID=34708761

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06069184A CO5700792A2 (es) 2003-12-19 2006-07-14 Un agente preventivo para la vasculitis

Country Status (22)

Country Link
US (1) US20140079695A1 (es)
EP (1) EP1707215B1 (es)
JP (1) JP4785534B2 (es)
KR (1) KR101218532B1 (es)
CN (1) CN1893979B (es)
AR (1) AR048210A1 (es)
AT (1) ATE549034T1 (es)
AU (1) AU2004305379B2 (es)
BR (1) BRPI0417072B8 (es)
CA (1) CA2549467C (es)
CO (1) CO5700792A2 (es)
DK (1) DK1707215T3 (es)
ES (1) ES2382809T3 (es)
HK (1) HK1095751A1 (es)
IL (1) IL176122A (es)
MY (1) MY142986A (es)
NO (1) NO20062718L (es)
NZ (1) NZ547645A (es)
RU (1) RU2379054C2 (es)
TW (1) TWI351967B (es)
WO (1) WO2005061000A1 (es)
ZA (1) ZA200604655B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324639A (ja) 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
EP1941907B1 (en) 2005-10-14 2016-03-23 Fukuoka University Inhibitor of transplanted islet dysfunction in islet transplantation
US8945558B2 (en) * 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007086490A1 (ja) 2006-01-27 2007-08-02 Keio University 脈絡膜血管新生を伴う疾患の治療剤
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
BRPI0806812B8 (pt) 2007-01-23 2021-09-14 Chugai Pharmaceutical Co Ltd Agente para suprimir reação de rejeição crônica e uso de um inibidor de il-6
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
KR101665729B1 (ko) 2008-06-05 2016-10-12 국립연구개발법인 고쿠리츠간켄큐센터 신경침윤 억제제
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI544077B (zh) 2009-03-19 2016-08-01 Chugai Pharmaceutical Co Ltd Antibody constant region change body
BRPI1011145A2 (pt) 2009-05-15 2016-03-15 Chugai Pharmaceutical Co Ltd anticorpo anti-axl
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
JP2013541594A (ja) 2010-11-08 2013-11-14 ジェネンテック， インコーポレイテッド 皮下投与される抗ｉｌ−６受容体抗体
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
EP3050896B1 (en) 2013-09-27 2021-07-07 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
BR112017014067B1 (pt) 2015-02-27 2021-01-12 Chugai Seiyaku Kabushiki Kaisha usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
WO2017115773A1 (ja) 2015-12-28 2017-07-06 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
RU2020111737A (ru) 2017-09-13 2021-10-13 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против il-6r и его антигенсвязывающий фрагмент и медицинское применение
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
MX2020009296A (es) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
JPH08311098A (ja) * 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
JPH10324639A (ja) * 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Ｉｌ−６アンタゴニストを有効成分として含有する感作ｔ細胞関与疾患の予防・治療剤
DE19923961A1 (de) * 1999-05-25 2000-11-30 Euro Nippon Kayaku Gmbh Verwendung von 15-Deoxyspergualin zur Behandlung von hyperreaktiven entzündlichen Erkrankungen und Autoimmunerkrankungen
JP2003026699A (ja) * 2001-07-13 2003-01-29 Inter Cyto Nano Science Co Ltd Ｉｌ−６シグナル伝達拮抗ペプチド
US7291721B2 (en) * 2001-11-14 2007-11-06 Centocor, Inc. Anti-IL-6 antibodies, compositions, methods and uses
FR2833011B1 (fr) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon Nouvelle proteine a activite inhibitrice de l'il-6
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
ES2382809T3 (es) 2012-06-13
HK1095751A1 (en) 2007-05-18
WO2005061000A1 (ja) 2005-07-07
NZ547645A (en) 2009-05-31
IL176122A0 (en) 2006-10-05
IL176122A (en) 2011-07-31
BRPI0417072B8 (pt) 2021-05-25
CN1893979B (zh) 2011-06-08
US20140079695A1 (en) 2014-03-20
TWI351967B (en) 2011-11-11
RU2006126092A (ru) 2008-01-27
AU2004305379B2 (en) 2011-04-07
BRPI0417072A (pt) 2007-03-13
AU2004305379A1 (en) 2005-07-07
BRPI0417072B1 (pt) 2017-10-24
CA2549467C (en) 2012-12-11
JPWO2005061000A1 (ja) 2007-07-12
KR101218532B1 (ko) 2013-01-03
DK1707215T3 (da) 2012-04-16
CN1893979A (zh) 2007-01-10
RU2379054C2 (ru) 2010-01-20
ATE549034T1 (de) 2012-03-15
KR20060132616A (ko) 2006-12-21
AR048210A1 (es) 2006-04-12
NO20062718L (no) 2006-09-18
ZA200604655B (en) 2007-11-28
EP1707215B1 (en) 2012-03-14
TW200524630A (en) 2005-08-01
MY142986A (en) 2011-02-14
EP1707215A1 (en) 2006-10-04
CA2549467A1 (en) 2005-07-07
JP4785534B2 (ja) 2011-10-05
EP1707215A4 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
CO5700792A2 (es) Un agente preventivo para la vasculitis
BR112021022497A2 (pt) Composto, composição farmacêutica, uso da composição farmacêutica, e, métodos para prevenir ou tratar obesidade, diabetes, inflamação e disfunção erétil
BRPI0415505A (pt) agente terapêutico para mesotelioma
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
BRPI0512674A (pt) compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
ATE530577T1 (de) Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
PE20081635A1 (es) Agentes para suprimir la reaccion de rechazo cronica
EA201390941A1 (ru) Аналоги глюкагона, проявляющие активность на рецепторе gip
TW200605907A (en) Preventing autoimmune disease
PE20120668A1 (es) Un compuesto n,n-dimetil-5-(2-metil-6-((5-metilpirazin-2-il)carbamoil)benzofuran-4-iloxi)pirimidin-carboxamida como activador de glucocinasa
IS2902B (is) Notkun á CGRP mótlyfsefnasamböndum fyrir meðhöndlun á sóra
UY28239A1 (es) Derivados de bencenosulfonamida
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
PA8847001A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
NO20080487L (no) Rekominant interferona2 (IFNa2) mutanter
EA201100609A1 (ru) Способы лечения воспаления
BRPI0608012A2 (pt) método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
ATE489098T1 (de) Pharmazeutische zusammensetzung mit einer salbe und zwei aufgelösten wirkstoffen
PH12019501900A1 (en) Treatment of hidradenitis suppurativa
DE602005021245D1 (de) 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
PE20081547A1 (es) Agentes terapeuticos que contienen un antagonista de interleucina-6 como ingrediente activo
DK2051710T3 (da) Sammensætninger og fremgangsmåder til behandling, reducering, forbedring eller lindring af sygdomme i det bageste øjensegment
PL405125A1 (pl) Cząsteczka miR172 pochodzenia roślinnego lub jej syntetyczny ekwiwalent, sposób zmniejszania proliferacji limfocytów B oraz zastosowanie cząsteczki miR172
AR044452A1 (es) Combinacion de un antagonista del receptor p2x7 y un inhibidor del factor de necrosis tumoral alfa

Legal Events

Date Code Title Description
FC Application refused